Hormonal and Mineral Changes in Early Stages of Chronic Kidney Diseases
Keywords:
divalent ion abnormality, CKD, calcitriol, secondary hyperparathyroidism, hyperphosphatemia, hypocalcemia, parathyroid hormone (PTH)
Abstract
This study evaluates divalent ion abnormalities (DIA) and the hormonal changes throughout the spectrum of early CKD stages (1-4) as defined by K/DOQI. A total of 96 patients (48.96% males, mean age 62±13 yrs) with CKD 1 to 4, were prospectively evaluated and followed-up. There were (20, 27, 32, and 17 patients in CKD-1, 2, 3, and 4 respectively). The diagnosis was confirmed by renal biopsy, Table -1.Mean serum creatinine (62±32 umol/L). Plasma levels of calcium, phosphorus, calcitriol (CTRL), and parathyroid hormone (PTH) were evaluated among the groups. A 24-hour urinary creatinine, calcium (Uca), phosphorus (Up), creatinine clearance and fractional excretion of calcium (FeCa), and phosphorus (FeP) were also compared. PTH was measured using the standard IRMA test (normal values 10-50 pg/dl), and calcitriol was measured by RIA test (normal values are 74.5 -169 pmol/l). The exclusion criteria are nephrolithiasis, hypercalcemia, proteinuria >3g/24 hrs, previous renal transplant, and therapy with steroids or anticonvulsants (Phenytoin).
Downloads
- Article PDF
- TEI XML Kaleidoscope (download in zip)* (Beta by AI)
- Lens* NISO JATS XML (Beta by AI)
- HTML Kaleidoscope* (Beta by AI)
- DBK XML Kaleidoscope (download in zip)* (Beta by AI)
- LaTeX pdf Kaleidoscope* (Beta by AI)
- EPUB Kaleidoscope* (Beta by AI)
- MD Kaleidoscope* (Beta by AI)
- FO Kaleidoscope* (Beta by AI)
- BIB Kaleidoscope* (Beta by AI)
- LaTeX Kaleidoscope* (Beta by AI)
How to Cite
References
Jones CA, McQuillan GM, Kusek JW (1998) Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. 32(6), 992-999. https://doi.org/10.1016/s0272-6386(98)70074-5
National Kidney Foundation (NKF), Kidney Disease Outcome Quality Initiative (K/DOQI), Advisory Board (2002) K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification, and stratification. 39(2 Suppl 2), S-249.
Fang Y, Ginsberg C, Sugatani T (2014) Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. 85, 142.
Pereira RC, Juppner H, Azucena-Serrano CE (2009) Pttren of FGF-23, DMPI, and MEPE expression in patients with chronic kidney disease. 45, 1161.
Sabbagh Y, Graciolli FG, O'Brien S (2012) Repression of osteocyte Wnt/B-catenin signaling is as early event in the progression of renal osteodystrophy. 27, 175.
Oliveira RB, Cancela AL, Graciolli FG (2010) Early control of PTH and FGF-23 in nonmorphosphatemic CKD patients a new target in CKD-MBD therapy?. 5, 286.
T. Isakova, P. Wahl, G. Vargas (2011) Correction to "Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease". 82(4), 498. https://doi.org/10.1038/ki.2012.143
Gutierrez O, Isakova T, Rhee E (2005) Fibroblast growth factor-23 mitigate hyperphosphatemia but accentuate calcitriol deficiency in chronic kidney disease. 16, 2205.
Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. 6, 913.
Levin A, Bakris GL, Molitch M (2007) Prevelance of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. 71, 31.
Pitts TO, Piraino BH, Mitro R (1988) Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. 67(5), 876. https://doi.org/10.1210/jcem-67-5-876
Martin KJ, Gonzalez EA (2007) Metabolic bone disease in chronic kidney disease. 18(3), 875. https://doi.org/10.1681/asn.2006070771
Davis Kates, Donald Sherrard, Dennis Andress (1997) Kates DM, Sherrard DJ, Andress DL. Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure. 30(6), 809-813. https://doi.org/10.1016/s0272-6386(97)90086-x
Hruska KA, Teitelbaum SL (1995) Renal osteodystrophy. 333, 166.
Fournier A, Moriniere P, Ben F (1992) Use of alkaline calcium salts as phosphate binder in uremic patients. 38, S50.
F. Liach (1995) Liach F, Secondary hyperparathyroidism in renal failure; The trade-off hypothesis revisited. 25(5), 663-679. https://doi.org/10.1016/0272-6386(95)90541-3
J. Silver, R. Levi (2005) Silver J, Levi R. Cellular and molecular mechanisms of secondary hyperparathyroidism. 63(02), 119-130. https://doi.org/10.5414/cnp63119
Wetmore JB, Liu S, Krebill R (2010) Effects of cinacalcet and concurrent low dose vitamin D on FGF23 levels in ESRD. 5, 110.
Saito H, Maeda A, Ohtomo S (2005) Circulating FGF- 23 is regulated by 1 alpha, 25 dihydroxyvitamin D3 and phosphorus in vivo. 280, 2543.
Koenig KG, Lindberg JS, Zerwekh JE (1992) Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease. 41(1), 161. https://doi.org/10.1038/ki.1992.22
Wilson L, Felsenfeld A, Drezner MK, Liach F (1985) Altered divalent ion metabolism in early renal failure: role of 1,25(OH)2D. 27(3), 565. https://doi.org/10.1038/ki.1985.48
Gutierrez OM, Isakova T, Andress DL (2008) Prevalence and severity of disordered mineral metabolism in blacks with chronic kidney disease. 73(8), 956. https://doi.org/10.1038/ki.2008.4
Chen Hsu, Sanjeevkumar Patel, Eric Young, Raymond Vanholder (1994) Hsu CH, Patel SR, Young EW, Vanholder R. The biological action of calcitriol in renal failure. 46(3), 605-612. https://doi.org/10.1038/ki.1994.312
Silver J, Naveh-Many T, Mayer H (1986) Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. 78(5), 1296. https://doi.org/10.1172/jci112714
Hartmut Malluche, Hanna Mawad, Nicholas Koszewski (2002) Malluche HH, Mawad H, Koszewski NJ. Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. 62(2), 367-374. https://doi.org/10.1046/j.1523-1755.2002.00450.x
P. Brumbaugh, M. Hughes, M. Haussler (1975) Brumbaugh PF, Hughes MR, Haussler MR. Cytoplasmic and nuclear binding components for 1- alpha 25-dihydroxyvitamin D3 in chick parathyroid glands. 72(12), 4871-4875. https://doi.org/10.1073/pnas.72.12.4871
Denda M, Finch J, Brown AJ (1996) 1,25- dihydroxyvitamin D3 and 22-oxacacitriol revent the decrease in vitamin D receptor content in parathyroid glands of uremic rats. 50(1), 34. https://doi.org/10.1038/ki.1996.283
Slatopolsky E, Weerts C, Thielan J (1984) Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. 74(6), 2136. https://doi.org/10.1172/jci111639
Fukuda N, Tanaka H, Tominaga Y (1993) Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. 92(3), 1436. https://doi.org/10.1172/jci116720
Rodriguez M, Nemeth E, Martin D (2005) The calciumsensing receptor: a key in the pathogenesis of secondary hyperparathyroidism. 288, F253.
Li YC, Amling M, Pirro AE (1998) Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. 139(10), 4391. https://doi.org/10.1210/endo.139.10.6262
Panda DK, Miao D, Bolivar I (2004) Inactivation of the 25-hydroxyvitamin D 1-alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. 279(16), 16754. https://doi.org/10.1074/jbc.m310271200
Published
2016-02-24
Issue
Section
License
Copyright (c) 2016 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.